BrainsWay Ltd. (BRSYF)
Healthcare · PNK
Price as at 30 Sept 2026, 16:42 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
BrainsWay Ltd. trades at $15.13, which is 44% above the $8.47 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 65 out of 100, which is a moat, but not a deep one. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 68.8 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
About BrainsWay Ltd.
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
BRSYF passes 3 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
BRSYF peers
The largest companies in the same industry (Medical Devices), then in the same sector.
- PHG Koninklijke Philips N.V.
- PEN Penumbra, Inc.
- GMED Globus Medical, Inc.
- BIO Bio-Rad Laboratories, Inc.
- LIVN LivaNova PLC
- IRTC iRhythm Holdings, Inc.
- TMDX TransMedics Group, Inc.
- NEOG Neogen Corporation
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is BrainsWay Ltd. (BRSYF) undervalued?
Against our fair value estimate of $8.47, BRSYF at $15.13 is 44% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
What is BRSYF's P/E ratio?
BRSYF trades at 68.8 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Where does SteadyShares get its BRSYF data?
Fundamentals for BRSYF come from company filings and exchange data, as listed on PNK; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 16:42 UTC and is delayed. Our data quality score for this company is 96/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for BRSYF, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.